vs
Side-by-side financial comparison of Sanara MedTech Inc. (SMTI) and Americas Gold & Silver Corp (USAS). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $19.1M, roughly 1.4× Americas Gold & Silver Corp). Sanara MedTech Inc. runs the higher net margin — -5.9% vs -82.3%, a 76.5% gap on every dollar of revenue. On growth, Sanara MedTech Inc. posted the faster year-over-year revenue change (4.6% vs -28.0%). Sanara MedTech Inc. produced more free cash flow last quarter ($3.9M vs $-41.3M).
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.
SMTI vs USAS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.5M | $19.1M |
| Net Profit | $-1.6M | $-15.7M |
| Gross Margin | 93.2% | 34.2% |
| Operating Margin | 23.5% | — |
| Net Margin | -5.9% | -82.3% |
| Revenue YoY | 4.6% | -28.0% |
| Net Profit YoY | 5.3% | 2.8% |
| EPS (diluted) | $-0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.3M | $19.1M | ||
| Q2 25 | $25.8M | — | ||
| Q1 25 | $23.4M | — | ||
| Q4 24 | $26.3M | — | ||
| Q3 24 | $21.7M | $26.5M | ||
| Q2 24 | $20.2M | — | ||
| Q1 24 | $18.5M | — |
| Q4 25 | $-1.6M | — | ||
| Q3 25 | $-30.4M | $-15.7M | ||
| Q2 25 | $-2.0M | — | ||
| Q1 25 | $-3.5M | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-2.9M | $-16.2M | ||
| Q2 24 | $-3.5M | — | ||
| Q1 24 | $-1.8M | — |
| Q4 25 | 93.2% | — | ||
| Q3 25 | 92.9% | 34.2% | ||
| Q2 25 | 92.5% | — | ||
| Q1 25 | 92.2% | — | ||
| Q4 24 | 91.4% | — | ||
| Q3 24 | 90.8% | 23.6% | ||
| Q2 24 | 90.0% | — | ||
| Q1 24 | 89.8% | — |
| Q4 25 | 23.5% | — | ||
| Q3 25 | 11.2% | — | ||
| Q2 25 | -0.1% | — | ||
| Q1 25 | -8.9% | — | ||
| Q4 24 | 18.6% | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | -14.3% | — | ||
| Q1 24 | -8.3% | — |
| Q4 25 | -5.9% | — | ||
| Q3 25 | -115.5% | -82.3% | ||
| Q2 25 | -7.8% | — | ||
| Q1 25 | -15.1% | — | ||
| Q4 24 | -6.5% | — | ||
| Q3 24 | -13.2% | -60.9% | ||
| Q2 24 | -17.4% | — | ||
| Q1 24 | -9.5% | — |
| Q4 25 | $-0.32 | — | ||
| Q3 25 | $-3.40 | — | ||
| Q2 25 | $-0.23 | — | ||
| Q1 25 | $-0.41 | — | ||
| Q4 24 | $-0.18 | — | ||
| Q3 24 | $-0.34 | — | ||
| Q2 24 | $-0.41 | — | ||
| Q1 24 | $-0.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.6M | $39.1M |
| Total DebtLower is stronger | $46.0M | — |
| Stockholders' EquityBook value | $5.9M | $50.2M |
| Total Assets | $72.9M | $234.7M |
| Debt / EquityLower = less leverage | 7.74× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.6M | — | ||
| Q3 25 | $14.9M | $39.1M | ||
| Q2 25 | $17.0M | — | ||
| Q1 25 | $20.7M | — | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $16.3M | — | ||
| Q2 24 | $6.2M | — | ||
| Q1 24 | $2.8M | — |
| Q4 25 | $46.0M | — | ||
| Q3 25 | $45.1M | — | ||
| Q2 25 | $44.2M | — | ||
| Q1 25 | $43.4M | — | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $14.4M | — | ||
| Q1 24 | $9.7M | — |
| Q4 25 | $5.9M | — | ||
| Q3 25 | $6.1M | $50.2M | ||
| Q2 25 | $35.4M | — | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $39.4M | — | ||
| Q3 24 | $39.8M | $53.1M | ||
| Q2 24 | $41.7M | — | ||
| Q1 24 | $43.3M | — |
| Q4 25 | $72.9M | — | ||
| Q3 25 | $71.1M | $234.7M | ||
| Q2 25 | $98.8M | — | ||
| Q1 25 | $96.4M | — | ||
| Q4 24 | $88.1M | — | ||
| Q3 24 | $88.5M | — | ||
| Q2 24 | $73.4M | — | ||
| Q1 24 | $70.9M | — |
| Q4 25 | 7.74× | — | ||
| Q3 25 | 7.33× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 1.18× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.9M | $-12.5M |
| Free Cash FlowOCF − Capex | $3.9M | $-41.3M |
| FCF MarginFCF / Revenue | 14.0% | -216.5% |
| Capex IntensityCapex / Revenue | 0.3% | 150.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.9M | — | ||
| Q3 25 | $2.2M | $-12.5M | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $-2.0M | — | ||
| Q4 24 | $932.0K | — | ||
| Q3 24 | $2.1M | $2.4M | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $-1.6M | — |
| Q4 25 | $3.9M | — | ||
| Q3 25 | $1.1M | $-41.3M | ||
| Q2 25 | $902.7K | — | ||
| Q1 25 | $-3.7M | — | ||
| Q4 24 | $859.9K | — | ||
| Q3 24 | $2.0M | $-11.2M | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-1.7M | — |
| Q4 25 | 14.0% | — | ||
| Q3 25 | 4.2% | -216.5% | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | -15.9% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 9.4% | -42.2% | ||
| Q2 24 | -7.3% | — | ||
| Q1 24 | -9.0% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 4.0% | 150.8% | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 7.4% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | 51.2% | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.4% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
USAS
Segment breakdown not available.
